Mass General Brigham Health Plan does not cover Wegovy for weight loss on most commercial plans as of January 1, 2026. The exclusion applies to individual and small-group commercial members. Wegovy is still covered when prescribed to reduce cardiovascular risk in certain patients, and some large-employer plans may keep weight-management coverage if the employer opts in at renewal. Every covered use requires prior authorization.
What Changed on January 1, 2026
Effective January 1, 2026, Mass General Brigham Health Plan removed GLP-1 medications carrying an obesity or weight-management indication from its individual and small-group commercial formularies.1Mass General Brigham Health Plan. Small Group Changes 2026 The excluded drugs are Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide). The plan told members the drug list was being updated “to help support your affordable premiums.”2Mass General Brigham Health Plan. Large Group Member Letter on GLP-1 Coverage
Large employer groups follow a different timeline. Employers with 50 or more enrolled subscribers can choose to add GLP-1 weight-management coverage when their plans renew during 2026.3Mass General Brigham Health Plan. GLP-1 Coverage Update So if you’re on a large-employer plan, whether Wegovy is still covered for weight loss depends on what your employer elected at renewal. Check with your HR benefits contact or call member services on the back of your ID card.
When Wegovy Is Still Covered
The exclusion targets the weight-management indication specifically. Wegovy also carries an FDA-approved indication for reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and a BMI of 27 or above, and the plan continues to cover it for that purpose.
To qualify under the plan’s pharmacy policy, you need a documented history of prior heart attack, stroke, or peripheral arterial disease, along with a BMI of at least 27, and you must be using the medication alongside lifestyle modifications like diet and exercise.4Mass General Brigham Health Plan. Weight Loss Medications Prior Authorization Policy (Commercial) The policy states that only Wegovy, among the GLP-1s, will be approved for this cardiovascular indication. Approvals last six months and require reauthorization.
Note that the diabetes exception does not apply to Wegovy. The plan still covers Ozempic, Mounjaro, and Trulicity for type 2 diabetes with prior authorization,3Mass General Brigham Health Plan. GLP-1 Coverage Update but Wegovy itself is not FDA-approved for diabetes.
Prior Authorization If Your Plan Still Covers Weight-Loss Use
For members on plans that still cover Wegovy for weight management (primarily large-group plans where the employer opted in), the criteria are specific.
Adults 18 and older need a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related comorbidity such as hypertension, type 2 diabetes, coronary heart disease, obstructive sleep apnea, or nonalcoholic steatohepatitis. You must also be actively participating in a behavioral modification program such as health coaching or nutritional counseling.4Mass General Brigham Health Plan. Weight Loss Medications Prior Authorization Policy (Commercial)
For adolescents aged 12 to 17, the threshold is a baseline BMI at or above the 95th percentile for age and sex, plus participation in a behavioral modification program.4Mass General Brigham Health Plan. Weight Loss Medications Prior Authorization Policy (Commercial)
Reauthorization every six months requires medical records showing continued enrollment in a behavioral program and at least 5% weight loss from baseline (for those treated up to six months) or maintained 5% weight loss for those treated longer. You cannot use Wegovy alongside another GLP-1 prescribed for type 2 diabetes. The quantity limit is four pens per 28 days.4Mass General Brigham Health Plan. Weight Loss Medications Prior Authorization Policy (Commercial)
MassHealth ACO Members
Members enrolled in Mass General Brigham’s MassHealth ACO plans face a separate cutoff. MassHealth is ending coverage for GLP-1 drugs used solely for weight loss effective July 1, 2026, and existing prior authorizations for weight loss expire June 30, 2026.5WBUR. Mass Cutting GLP-1 Coverage Medicaid Wegovy Zepbound
After that date, Wegovy remains available through MassHealth only for non-weight-loss indications: established cardiovascular disease, metabolic dysfunction-associated steatohepatitis, or moderate to severe obstructive sleep apnea in adults with a BMI over 30.6Mass General Brigham Health Plan. May 2026 Provider Notification on MassHealth Weight Loss Changes Members younger than 21 may have claims reviewed under federal Early and Periodic Screening, Diagnostic, and Treatment requirements, but new adolescent patients will be required to try phentermine first.
Medicare Members
Medicare Part D has historically not covered drugs prescribed solely for weight loss. Starting July 1, 2026, CMS launched the Medicare GLP-1 Bridge, a temporary demonstration program running through December 31, 2027, that gives eligible Medicare beneficiaries access to Wegovy and Zepbound for weight management at a flat $50 copay per monthly supply.7CMS. Medicare GLP-1 Bridge
The program is administered centrally by Humana rather than through individual Part D plans, and requires a prior authorization attesting to specific BMI thresholds.8CMS. Medicare GLP-1 Bridge Information for Part D Plans Beneficiaries who use Wegovy for an indication already covered under standard Part D, such as cardiovascular risk reduction, go through their regular Part D plan instead.
If You’ve Lost Coverage
Other Weight-Loss Medications Still on the Formulary
The plan continues to cover several non-GLP-1 weight-loss medications, all requiring prior authorization: Alli (orlistat), an over-the-counter fat absorption blocker; Contrave (naltrexone/bupropion), a combination pill targeting appetite and cravings; phentermine, a short-term appetite suppressant; and Qsymia (phentermine/topiramate extended-release), a combination appetite suppressant.3Mass General Brigham Health Plan. GLP-1 Coverage Update
Wellness Programs and Bariatric Surgery
The plan offers non-pharmacological weight-management resources, including a year-long “Healthier You” program, a digital weight management program through Teladoc Health with expert coaching and a smart scale, free one-on-one health coaching by phone, reimbursements for qualified fitness facilities, and up to six months of membership fees for qualified weight-loss programs.3Mass General Brigham Health Plan. GLP-1 Coverage Update
Bariatric surgery remains a covered benefit for commercial members. Eligible adults generally need a BMI of 40 or above, or a BMI of 35 or above with a high-risk comorbid condition such as type 2 diabetes, coronary heart disease, or obstructive sleep apnea. Candidates must also have documented unsuccessful attempts at physician-supervised weight loss and participate in pre- and post-operative management programs. Covered procedures include Roux-en-Y gastric bypass, sleeve gastrectomy, and laparoscopic adjustable gastric banding, among others.9Mass General Brigham Health Plan. Bariatric Surgery Provider Policy Guidelines
Paying Out of Pocket
If you want to continue Wegovy without insurance coverage, Novo Nordisk’s self-pay savings program offers Wegovy injection starting at $199 per month for the lowest doses and $349 per month for maintenance doses. A tablet formulation is available starting at $149 per month for the 1.5 mg and 4 mg strengths.10Wegovy. What to Pay for Wegovy If you still have commercial insurance on a plan that covers Wegovy, a manufacturer savings card may bring your cost to as little as $25 per month. Enrollment is through NovoCare or by texting “SAVE” to 83757.11NovoMedLink. Wegovy Patient Savings
The Novo Nordisk Patient Assistance Program provides free medication to qualifying uninsured patients or Medicare beneficiaries who meet income limits, but it is not available to patients with private or commercial insurance.12NovoCare. Patient Assistance Program HSA and FSA funds can be used to pay for the medication.
Appeals
Because excluding GLP-1s for weight loss is a benefit design decision rather than a medical necessity denial, this type of denial is generally not reviewable through standard medical necessity appeals. Blue Cross Blue Shield of Massachusetts has stated that for its members; Mass General Brigham Health Plan has not publicly addressed whether the same limitation applies to its members.13Blue Cross Blue Shield of Massachusetts. Account-Broker GLP-1 FAQs
Massachusetts law does provide for external review through the Office of Patient Protection when a health insurer issues a denial based on medical necessity, but you must first exhaust the insurer’s internal grievance process. An external review request must be filed within four months of a final adverse determination, and the external reviewer’s decision is binding.14Mass.gov. Request an External Review of a Health Insurance Decision If you believe your medical circumstances qualify under a non-weight-loss indication like cardiovascular risk reduction, talk with your prescribing physician about submitting a new prior authorization under that criterion.